跳转至内容
Merck
CN
  • The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance.

The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance.

Journal of immunology (Baltimore, Md. : 1950) (2013-09-18)
Julia Phieler, Kyoung-Jin Chung, Antonios Chatzigeorgiou, Anne Klotzsche-von Ameln, Ruben Garcia-Martin, David Sprott, Maria Moisidou, Theodora Tzanavari, Barbara Ludwig, Elena Baraban, Monika Ehrhart-Bornstein, Stefan R Bornstein, Hassan Mziaut, Michele Solimena, Katia P Karalis, Matina Economopoulou, John D Lambris, Triantafyllos Chavakis
摘要

Obese adipose tissue (AT) inflammation contributes critically to development of insulin resistance. The complement anaphylatoxin C5a receptor (C5aR) has been implicated in inflammatory processes and as regulator of macrophage activation and polarization. However, the role of C5aR in obesity and AT inflammation has not been addressed. We engaged the model of diet-induced obesity and found that expression of C5aR was significantly upregulated in the obese AT, compared with lean AT. In addition, C5a was present in obese AT in the proximity of macrophage-rich crownlike structures. C5aR-sufficient and -deficient mice were fed a high-fat diet (HFD) or a normal diet (ND). C5aR deficiency was associated with increased AT weight upon ND feeding in males, but not in females, and with increased adipocyte size upon ND and HFD conditions in males. However, obese C5aR(-/-) mice displayed improved systemic and AT insulin sensitivity. Improved AT insulin sensitivity in C5aR(-/-) mice was associated with reduced accumulation of total and proinflammatory M1 macrophages in the obese AT, increased expression of IL-10, and decreased AT fibrosis. In contrast, no difference in β cell mass was observed owing to C5aR deficiency under an HFD. These results suggest that C5aR contributes to macrophage accumulation and M1 polarization in the obese AT and thereby to AT dysfunction and development of AT insulin resistance.